Clinical research of the regulating effects of QinHuangFang on the inmmune function and gut microbiota composition of post-chemotherapy DLBCL patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064856

Enrollment

Unknown

Registered

2022-10-20

Start date

2020-11-06

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diffuse large B-cell lymphoma (DLBCL)

Interventions

Experimantal group:QinHuangFang

Blank control group:None

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years; 2. Diagnosed diffuse large B cell lymphoma; 3. Completed at least 4 cycles of R-CHOP and acquired CR; 4. Within 2 years after finishing R-CHOP.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors; 2. Immune disease or digestive system disease; 3. Abnormal liver and kidney function (an index exceeding 2.5 times the upper limit of normal value according to WHO Classification Standard for Common Toxic and Side Effects of Anticancer Drugs); 4. Those who have used or are using antibiotics, probiotics, other immunomodulators or traditional Chinese medicine within the past month; 5. After collection or transplantation of autologous bone marrow hematopoietic stem cells; 6. Pregnant or lactating; 7. Allergic to research interventions; 8. Long-term smoking.

Design outcomes

Primary

Measure	Time frame
CD4+ count;	—

Secondary

Measure	Time frame
CD8 ratio;CD3 ratio;CD4/CD28 ratio;CD8/CD28 ratio;	—

Countries

China

Contacts

Public ContactZhu Weirong

willonzhu@163.com+86 13651928161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026